AbbVie starts second Phase III veliparib study
This article was originally published in Scrip
Executive Summary
AbbVie has two late-stage entries in the race to bring a poly ADP-ribose polymerase (PARP) inhibitor to market now that it has kicked off a second Phase III clinical trial for veliparib – this time for the treatment of lung cancer.